Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Hematology Boards > Malignant Hematology > Flashcards

Malignant Hematology Flashcards

1
Q

Immunophenotype for HCL variant

A

BRAF V600E negative

CD19, CD20, CD22 positive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Who to use high dose dauno in

A

age <65

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Treatment of APL after CR2

A

Auto if PCR neg

Allo if PCR pos

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Steroid resposiveness in COP vs BO

A

COP - responsive

BO - not responsive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

17p in CLL prognosis

A

Very bad prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

11q in CLL prognosis

A

Bad prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

13q in CLL prognosis

A

Very good prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Treatment of 17p CLL

A

ibrutinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Immunophenotype of HCL (4)

A

CD19+, CD20+, CD103+, CD11c+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Ibrutinib resistance mutation

A

C481S

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Difference between classical and variant HCL mutation

A

BRAF V600E

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Third line treatment for HCL

A

Moxetumomab pasudotox-tdfk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Treatment of PRCA in CLL

A

Immunosuppresive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Treatment of Stage I-II unfavorable HL

A

ABVD x 4 followed by ISRT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Unfavorable features for HL (5)

A 
Bulky mediastinum
>10cm disease
B symptoms
ESR >50
>3 sites of disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

IHC finding for nodular lymphocyte predominant HL

A

CD20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Treatment of stage III-IV HL if Deauville 1-3 after 2 cycles of ABVD

A

AVD x 4 more cycles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Treatment of stage III-IV HL if Deauville 4+ after 2 cycles of ABVD

A

BEACOPP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Treatment of HL during pregnancy

A

ABVD in the second trimester

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

MOA of siltuximab

A

IL-6 antagonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

t(3;14) for DLBCL prognosis

A

Good prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Treatment of Stage IA nodular lymphocyte predominant HL

A

ISRT alone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Karyotype for alkalating agent MDS/AML

A

-5 or -7

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Childhood MDS with -7 gene mutation

A

SAMD9

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Dosing of lenalidomide in HD

A

5mg daily, after dialysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Adverse risk MM cytogenetics (5)

A 
t(4;14)
t(14;20)
t(14;16)
del17p
amp 1q21
27
Q

Indications for plasmapheresis in WM (2)

A

Hyperviscosity symptoms OR

IgM >4000

28
Q

Karyotype in FL

29
Q

Definition of grade 3b FL

A

15 centroblasts or sheets of centroblasts

30
Q

MALT t(11;18) meaning for response to triple therapy

A

Lack of benefit

31
Q

Lymphoma associated with HCV

A

Splenic marginal zone lymphoma

32
Q

Treatment of aggressive Mantle Cell in young patient

33
Q

Treatment of NK/T-cell lymphoma

A

Chemoradiation

34
Q

Rosai Dorfman disease clinical symptoms

A

Hisitiocytes

LAD

35
Q

T-cell prolymphocytic leukemia karyotype

A

inv(14)(q11q32)

36
Q

Plasmablastic lymphoma treatment

A

EPOCH with IT chemo

37
Q

Treatment of refractory mantle cell lymphoma

A

BTK inhibitors
R/R
VEN

38
Q

Definition of bulky disease in DLBCL

39
Q

Burkitt lymphoma translocation

40
Q

Mantel cell lymphoma translocation

41
Q

Follicular lymphoma translocation

42
Q

Infections with PI3K inhibitors (2)

43
Q

Mutation associated with Erdheim-Chester disease

A

BRAF V600E

44
Q

Diagnostic antigens in mantle cell lymphoma

A

CCND1

SOX11

45
Q

EBV+ lymphoma with rash an effusions

A

Angioimmunoblastic T-cell lymphoma

46
Q

Brexucabtagene autoleucel disease

A

Mantle cell lymphoma

47
Q

Maintenance after auto for mantle cell

A

Rituximab x 3 years

48
Q

Adverse cytogenetics in AL amyloid

49
Q

Treatment of ATTR amyloidosis

A

liver transplantation

50
Q

Treatment of ATTR amyloidosis with peripheral neuropathy

51
Q

Treatment of ATTR amyloidosis with cardiac involvement in non liver transplant setting

52
Q

HMR in MF

A

EZH2, ASXL1, SRSF2, IDH1/2

53
Q

BCL6 positive malignancy

A

Follicular lymphoma

54
Q

Most permissive loci for allo transplant

55
Q

Most common fungal infection with ibrutinib

A

Aspergillosis

56
Q

Risk for post transplant LPD

57
Q

TKI to avoid in DM

58
Q

Upfront treatment of ALCL

A

Brentuximab+CHP

59
Q

Treatment of elderly CLL

A

Obinutuzumab + Chlorambucil

60
Q

Treatment of 17p CLL R/R to BTK

A

Venetoclax

61
Q

Time after alloSCT for live vaccines

62
Q

Timing of PTLD post transplant as it relates to EBV related

A

<1 year: EBV related

>1 year: not EBV related

63
Q

Stains for erythroleukemia (2)

A

glycophorin A

CD36

Hematology Boards (2 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions